Forest Pharmaceuticals Inc
FDA Regulatory Profile
Summary
- Total Recalls
- 6
- 510(k) Clearances
- 0
- Inspections
- 5
- Compliance Actions
- 0
Recent Recalls
| Number | Class | Product | Date |
|---|
| D-0036-2015 | Class II | Bystolic (nebivolol) tablets, 20 mg/tablet, packaged as 7 tablets/bottle/carton, and 12 bottles/tray | September 26, 2014 |
| D-1412-2014 | Class II | Bystolic (nebivolol) tablets, 20 mg/tablet. 7 Tablet Professional Sample Bottle, Rx Only. Forest Ph | June 19, 2014 |
| D-1348-2014 | Class II | Bystolic (nebivolol), 20 mg/tablet, 30 tablets per bottle, Rx only, Licensed from Mylan Laboratories | May 12, 2014 |
| D-1065-2014 | Class III | Namenda XR (memantine HCl), sample pack, 28 mg, extended release capsules, packaged in 5-count sampl | November 13, 2013 |
| D-1064-2014 | Class III | Namenda XR (memantine HCl), titration pack (7 mg, 14 mg, 21 mg and 28 mg) extended release capsules, | November 13, 2013 |
| D-1063-2014 | Class III | Namenda XR (memantine HCl), 7 mg extended release capsules, 30-count bottle, Rx only, Forest Pharmac | November 13, 2013 |